The refit model for end-stage liver disease-Na is not a better predictor of mortality than the refit model for end-stage liver disease in patients with cirrhosis and ascites

被引:4
|
作者
Kim, Jun Jae [1 ]
Kim, Jeong Han [1 ]
Koo, Ja Kyung [1 ]
Choi, Yun Jung [1 ]
Ko, Soon Young [1 ]
Choe, Won Hyeok [1 ]
Kwon, So Young [1 ]
机构
[1] Konkuk Univ, Sch Med, Digest Dis Ctr, Dept Internal Med, Seoul, South Korea
关键词
End Stage Liver Disease; Liver Cirrhosis; Ascites; Mortality; Hyponatremia;
D O I
10.3350/cmh.2014.20.1.47
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: The modification of the Model for End-Stage Liver Disease (MELD) scoring system (Refit MELD) and the modification of MELD-Na (Refit MELDNa), which optimized the MELD coefficients, were published in 2011. We aimed to validate the superiority of the Refit MELDNa over the Refit MELD for the prediction of 3-month mortality in Korean patients with cirrhosis and ascites. Methods: We reviewed the medical records of patients admitted with hepatic cirrhosis and ascites to the Konkuk University Hospital between January 2006 and December 2011. The Refit MELD and Refit MELDNa were compared using the predictive value of the 3-month mortality, as assessed by the Child-Pugh score. Results: In total, 530 patients were enrolled, 87 of whom died within 3 months. Alcohol was the most common etiology of their cirrhosis (n= 271, 51.1%), and the most common cause of death was variceal bleeding (n= 20, 23%). The areas under the receiver operating curve (AUROCs) for the Child-Pugh, Refit MELD, and Refit MELDNa scores were 0.754, 0.791, and 0.764 respectively; the corresponding values when the analysis was performed only in patients with persistent ascites (n= 115) were 0.725, 0.804, and 0.796, respectively. The significant difference found among the Child-Pugh, Refit MELD, and Refit MELDNa scores was between the Child-Pugh score and Refit MELD in patients with persistent ascites (P= 0.039). Conclusions: Refit MELD and Refit MELDNa exhibited good predictability for 3-month mortality in patients with cirrhosis and ascites. However, Refit MELDNa was not found to be a better predictor than Refit MELD, despite the known relationship between hyponatremia and mortality in cirrhotic patients with ascites.
引用
收藏
页码:47 / 55
页数:9
相关论文
共 50 条
  • [1] Predictive value of Refit Model for End-Stage Liver Disease, Refit Model for End-Stage Liver Disease-Na, and pre-existing scoring system for 3-month mortality in Korean patients with cirrhosis
    Koo, Ja Kyung
    Kim, Jeong Han
    Choi, Yun Jung
    Lee, Cho I.
    Yang, Jae Hoon
    Yoon, Hyeon Young
    Choi, Hye Jin
    Ko, Soon Young
    Choe, Won Hyeok
    Kwon, So Young
    Lee, Chang Hong
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 (07) : 1209 - 1216
  • [2] The Model for End-stage Liver Disease 3.0 is not superior to the Model for End-stage Liver Disease-Na in predicting survival: A retrospective cohort study
    Duan, Fangfang
    Liu, Chen
    Zhai, Hang
    Quan, Min
    Cheng, Jun
    Yang, Song
    HEPATOLOGY COMMUNICATIONS, 2023, 7 (10)
  • [3] Model for End-stage Liver Disease and Model for End-stage Liver Disease-Na Scores Predict Both Before-Listing and Wait-List Mortality
    Yamashiki, N.
    Sugawara, Y.
    Tamura, S.
    Kaneko, J.
    Nojiri, K.
    Aoki, T.
    Sakamoto, Y.
    Hasegawa, K.
    Koike, K.
    Kokudo, N.
    TRANSPLANTATION PROCEEDINGS, 2012, 44 (02) : 389 - 392
  • [4] Mortality in patients with end-stage liver disease above model for end-stage liver disease 3.0 of 40
    Tarlow, Branden D.
    Kim, W. Ray
    Mannalithara, Ajitha
    Kwo, Paul Y.
    Bonham, C. Andrew
    Kwong, Allison
    HEPATOLOGY, 2023, 77 (03) : 851 - 861
  • [5] Model for End-stage Liver Disease
    Singal, Ashwani K.
    Kamath, Patrick S.
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2013, 3 (01) : 50 - 60
  • [6] Important predictor of mortality in patients with end-stage liver disease
    Kim, Hyung Joon
    Lee, Hyun Woong
    CLINICAL AND MOLECULAR HEPATOLOGY, 2013, 19 (02) : 105 - 115
  • [7] Model for end-stage liver disease (MELD) exception for ascites
    Biggins, Scott W.
    Colquhoun, Steven
    Gish, Robert G.
    Runyon, Bruce A.
    LIVER TRANSPLANTATION, 2006, 12 (12) : S88 - S90
  • [8] Applying the original model for end-stage liver disease score rather than the model for end-stage liver disease-Na score for risk stratification prior to transjugular intrahepatic portosystemic shunt procedures
    Lee, Brian T.
    Yang, Alexander H.
    Urban, Seth
    Kim, Ki-Yoon
    Ter-Oganesyan, Ramon
    Yuan, Liyun
    Han, Hyosun H.
    Khemichian, Saro
    Kahn, Jeffrey A.
    Kim, Brian
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (04) : 541 - 546
  • [9] Liver transplantation outcomes under the model for end-stage liver disease and pediatric end-stage liver disease
    Freeman, RB
    Harper, A
    Edwards, EB
    CURRENT OPINION IN ORGAN TRANSPLANTATION, 2005, 10 (02) : 90 - 94
  • [10] Model for End-Stage Liver Disease Sodium as a Predictor of Surgical Risk in Cirrhotic Patients With Ascites
    Maassel, Nathan L.
    Fleming, Matthew M.
    Luo, Jiajun
    Zhang, Yawei
    Pei, Kevin Y.
    JOURNAL OF SURGICAL RESEARCH, 2020, 250 : 45 - 52